Business Wire

Veza, the Data Security Platform Built on the Power of Authorization, Announces Blackstone as a Customer and Strategic Series C Investor

22.6.2022 19:00:00 EEST | Business Wire | Press release

Share

Veza, the data security platform built on the power of authorization, announced an investment in their Series C funding round from Blackstone Innovations Investments, along with participation from previous investors. To date, Veza has raised a total of $110 million from top-tier investors including Accel, Bain Capital, Ballistic Ventures, GV, Norwest Venture Partners, True Ventures, and others. Blackstone has also selected Veza to help modernize its data security and access governance.

Veza empowers organizations to address today’s greatest cybersecurity challenge: who can and should take what action on what data. As the world increasingly moves online, our changing behaviors are driving a transformational shift toward multi-cloud data systems, apps, computing, and infrastructure. This shift creates a complex, distributed web of human identities, accounts, apps, services, and access points that are constantly changing and susceptible to vulnerabilities. To address this, Veza takes a comprehensive approach that pulls together authorization data from disparate systems, giving customers a single source of truth to manage data access and controls.

“Having a world-class cybersecurity program that protects our brand, reputation, investors and intellectual property is of paramount importance to our firm, and we are continuing to incorporate innovative technology solutions,” says Adam Fletcher, Chief Security Officer at Blackstone. “Our team is always looking for ways to develop a more comprehensive view of access across all of our applications and cloud infrastructure to allow us to modernize the firm’s access controls. We are excited to partner with Veza to help us accomplish this.”

“Blackstone Innovations Investments is committed to investing in cutting-edge technology companies that we believe will have a meaningful impact on Blackstone, our portfolio companies, and the broader industry. We look forward to working with Veza and their impressive leadership team as they enter this next phase of growth,” comments Stevi Petrelli, Head of Blackstone Innovations Investments.

“Institutions across multiple industries view Blackstone as an example of exceptional technology deployment and cybersecurity expertise,” says Tarun Thakur, CEO and Co-Founder of Veza. “Veza has greatly benefited from Blackstone’s product feedback and market insights. We are thrilled to work with Blackstone’s Security team to further modernize data security for their hybrid and multi-cloud environment.”

Additional investment in Veza comes from notable entrepreneurs including Dheeraj Pandey, Co-founder & CEO, DevRev and former CEO, Nutanix, and Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO, SuccessFactors.

“Authorization is the source of truth when it comes to understanding who has access to what,” says Dheeraj Pandey, Co-Founder and CEO of DevRev. “Understanding authorization at scale is one of the hardest problems to address and I am excited to watch team Veza bring on a new era of identity, rooted in authorization. Veza is defining authorization as a standard for protecting data against ransomware and other forms of data breach.”

“Entrepreneurs will tell you that company building is one of the hardest, yet rewarding experiences, with real potential to make an impact,” says Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO SuccessFactors. “When evaluating any company, I look for deep technical breakthrough for a massive market opportunity, deal composition and company traction, and passion amongst founders. And, I’m very excited to be partnering with Tarun and Veza on the mission to build an iconic company that will revolutionize the data security industry for decades to come.”

About Veza

Veza is the data security platform built on the power of authorization. Our platform is purpose-built for hybrid multi-cloud environments to help you use and share your data safely. Veza makes it easy to understand, manage, and control who can and should take what action on what data. We organize authorization metadata across identity providers, data systems, cloud service providers, and applications — all to address the toughest data security challenges of the modern era. Founded in 2020, the company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures. To learn more, please visit us at veza.com. Many Fortune 500, Fortune 1000 and smaller organizations use its data security platform for protection against ransomware, modernizing access governance for critical data and apps, and implementing data lake security for Snowflake and other solutions. Follow Veza on LinkedIn or on Twitter @vezainc.

About Blackstone

Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $915 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.

Learn more about Veza:
Get started with Veza Free Trial
Veza for Snowflake Access Governance
Modernize Privileged Access for Data
Explore Veza’s Open Authorization API (OAA) for SaaS applications (GitHub, and more)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Teju Shyamsundar
tshyamsundar@veza.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye